Literature DB >> 23365082

Immunopathology of immune reconstitution inflammatory syndrome in Whipple's disease.

Verena Moos1, Gerhard E Feurle, Katina Schinnerling, Anika Geelhaar, Julian Friebel, Kristina Allers, Annette Moter, Judith Kikhney, Christoph Loddenkemper, Anja A Kühl, Ulrike Erben, Florence Fenollar, Didier Raoult, Thomas Schneider.   

Abstract

During antimicrobial treatment of classic Whipple's disease (CWD), the chronic systemic infection with Tropheryma whipplei, immune reconstitution inflammatory syndrome (IRIS), is a serious complication. The aim of our study was to characterize the immunological processes underlying IRIS in CWD. Following the definition of IRIS, we describe histological features of IRIS and immunological parameters of 24 CWD IRIS patients, 189 CWD patients without IRIS, and 89 healthy individuals. T cell reconstitution, Th1 reactivity, and the phenotype of T cells were described in the peripheral blood, and infiltration of CD4(+) T cells and regulatory T cells in the duodenal mucosa was determined. During IRIS, tissues were heavily infiltrated by CD3(+), predominantly CD45RO(+)CD4(+) T cells. In the periphery, initial reduction of CD4(+) cell counts and their reconstitution on treatment was more pronounced in CWD patients with IRIS than in those without IRIS. The ratio of activated and regulatory CD4(+) T cells, nonspecific Th1 reactivity, and the proportion of naive among CD4(+) T cells was high, whereas serum IL-10 was low during IRIS. T. whipplei-specific Th1 reactivity remained suppressed before and after emergence of IRIS. The findings that IRIS in CWD mainly are mediated by nonspecific activation of CD4(+) T cells and that it is not sufficiently counterbalanced by regulatory T cells indicate that flare-up of pathogen-specific immunoreactivity is not instrumental in the pathogenesis of IRIS in CWD.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23365082     DOI: 10.4049/jimmunol.1202171

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  7 in total

1.  "Immune reconstitution inflammatory syndrome"-a rare complication of Whipple's disease.

Authors:  S Kapoor
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-04-07       Impact factor: 3.267

Review 2.  Clinical Manifestations, Treatment, and Diagnosis of Tropheryma whipplei Infections.

Authors:  Ruben A V Dolmans; C H Edwin Boel; Miangela M Lacle; Johannes G Kusters
Journal:  Clin Microbiol Rev       Date:  2017-04       Impact factor: 26.132

Review 3.  Emerging trends in COVID-19 treatment: learning from inflammatory conditions associated with cellular therapies.

Authors:  Maria Cancio; Rachele Ciccocioppo; Patricia R M Rocco; Bruce L Levine; Vincenzo Bronte; Catherine M Bollard; Daniel Weiss; Jaap Jan Boelens; Patrick J Hanley
Journal:  Cytotherapy       Date:  2020-05-07       Impact factor: 5.414

4.  Intestinal barrier dysfunction mediates Whipple's disease immune reconstitution inflammatory syndrome (IRIS).

Authors:  Julian Friebel; Katina Schinnerling; Anika Geelhaar-Karsch; Kristina Allers; Thomas Schneider; Verena Moos
Journal:  Immun Inflamm Dis       Date:  2022-05

5.  Primary Whipple disease of the brain: case report with long-term clinical and MRI follow-up.

Authors:  Jan Peregrin; Hana Malikova
Journal:  Neuropsychiatr Dis Treat       Date:  2015-09-25       Impact factor: 2.570

6.  Potential Role for Urine Polymerase Chain Reaction in the Diagnosis of Whipple's Disease.

Authors:  Annette Moter; Matthias Janneck; Manuel Wolters; Christof Iking-Konert; Alexandra Wiessner; Christoph Loddenkemper; Björn Hartleben; Marc Lütgehetmann; Julia Schmidt; Ulrike Langbehn; Sabrina Janssen; Anika Geelhaar-Karsch; Thomas Schneider; Verena Moos; Holger Rohde; Judith Kikhney; Thorsten Wiech
Journal:  Clin Infect Dis       Date:  2019-03-19       Impact factor: 9.079

7.  Differential diagnostic value of rheumatic symptoms in patients with Whipple's disease.

Authors:  Gerhard E Feurle; Verena Moos; Andrea Stroux; Nadine Gehrmann-Sommer; Denis Poddubnyy; Christoph Fiehn; Thomas Schneider
Journal:  Sci Rep       Date:  2021-03-16       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.